Invenshure

Invenshure

Invenshure was co-founded in 2012 by Danny Cunagin and Troy Kopischke. The firm operates a hybrid model that combines an in-house venture studio with a more conventional venture capital arm, sourcing proprietary deal flow by originating companies around deep-tech intellectual property, much of it spun out of the University of Minnesota and the Mayo Clinic. That structure gives it a material information advantage in early-stage medical and hard-science investing relative to peers who only evaluate externally sourced pitch decks. Investment activity spans medical devices, health technology, enterprise AI, and industrial automation. Invenshure's portfolio includes historically notable positions in HistoSonics, a developer of non-invasive histotripsy platforms for liver-tumor ablation, and Oncode Therapeutics, an oncology company targeting solid tumors through a novel onchocladin-small-molecule program. The firm typically enters at formation or pre-seed, often providing the first $1–3 million of capital, and has taken some portfolio companies through multiple financing rounds and regulatory milestones, including FDA IDE approvals. Its geographic focus concentrates on the Upper Midwest and select national opportunities where the intellectual-property origination model repeats. Invenshure runs a lean organizational structure; key operational and scientific advisors are embedded on a company-by-company basis rather than housed as a large centralized investment team. The firm has not publicly disclosed aggregate assets under management or total capital deployed, though its track record of downstream syndications with coastal life-science funds reflects institutional recognition of its origination quality. A notable operational event came in August 2023 when portfolio company HistoSonics raised an $85 million Series D from Johnson & Johnson Innovation and others, further validating the firm's model of building companies from concept to late-clinical-stage assets (per HistoSonics press release, August 2023). What distinguishes Invenshure structurally is its parallel operation as both an incubator and a fiduciary investor. It does not simply fund founders; it co-invents the foundational intellectual property and recruits management teams around it, retaining significant ownership through an active-build phase that can last five to seven years. This replaces the typical venture firm’s sourcing risk with execution risk, making Invenshure behave more like an internally funded R&D shop with a venture fund’s return profile than a pure financial LP-GP intermediary.